

AMENDMENTS TO THE SPECIFICATION:

Please replace the paragraph starting line 27 on page 9, with the following:

Figure [[9]] **9a** presents results of an experiment to measure competitive inhibition of Anti-C5aR MAb binding to L1.2 cells transfected with human C5aR by the C5aR N-terminal peptide PEPI.

Please insert the following paragraph after the paragraph starting line 27 on page 9:

Figure 9b presents results of an experiment measuring FACS staining of purified neutrophils with MAb 7F3 in the presence and absence of the C5aR N-terminal peptide PEPI.

Please replace the paragraph starting line 32 on page 9, with the following:

Figure 10 presents results of an ~~experiment measuring FACS staining of purified neutrophils with~~ **ELISA assay measuring reactivity of MAb 6C12, F3 and 12D4 to in the presence and absence of the C5aR N-terminal 9-29 ("PEPI") and OPG peptide PEPI.**

Please replace the paragraph starting line 10 on page 12, with the following:

The hybridoma which produces the monoclonal antibody designated 12D4 (~~12D4-P9~~) **(12D4-N17)** was deposited on ~~2-September-2002~~ **September 8, 2004** with ECACC under accession number ~~02090227~~ **04090801** (European Collection of Cell Cultures (ECACC), Porton Down, Salisbury, Wiltshire, SP4 0JG, United Kingdom).

Please replace the paragraph starting line 1 on page 46, with the following:

Figure 8 [[(a)]] shows that all three MAbs exhibited inhibition of neutrophil migration towards IL-8. 7F3 MAb (both dialysed and non-dialysed) was the most effective inhibitor resulting in a 5-fold reduction in neutrophil migration numbers.

Please replace line 33 on page 47, with the following:

12D4: heavy chain IgG3 **IgG2b**